There are currently 93 active clinical trials seeking participants for Sickle Cell Disease research studies. The states with the highest number of trials for Sickle Cell Disease participants are New York, North Carolina, California and Georgia.
Cannabidiol in Sickle Cell Disease
NCT06930703
Recruiting
Randomized, placebo-controlled, double masked, dose finding study of twice daily cannabidiol given at 3 dose levels, 200mg, 400mg, and 600mg, compared to placebo for 4 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Icahn School of Medicine at Mount Sinai, Manhattan, New York
Conditions: Sickle Cell Disease
Register for Updates
Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
NCT06385886
Recruiting
The goal of this observational study is to help us understand more about the best ways to help individuals living with Sickle Cell Disease (SCD) get the best care. The main question it aims to answer is: How to find individuals unaffiliated from SCD specialist care use three distinct pathways? Once unaffiliated individuals are found using the pathways, Investigators will employ linkage coordinators (trained staff) to engage these patients in care. Participants will be asked to fill out an assess... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: University of Alabama, Birmingham (UAB), Birmingham, Alabama +8 locations
Conditions: Sickle Cell Disease
Register for Updates
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
NCT06924970
Recruiting
The main purpose of this study is to compare the effect of tebapivat versus placebo on anemia and to detect a dose-response for hemoglobin (Hb) response in participants with SCD.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
06/19/2025
Locations: MedStar Washington Hospital Center, Washington, District of Columbia +1 locations
Conditions: Sickle Cell Disease
Register for Updates
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268
Recruiting
This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the par... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
06/19/2025
Locations: Uni of Alabama at Birmingham, Birmingham, Alabama +160 locations
Conditions: Sickle Cell Disease
Register for Updates
Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia
NCT04109820
Recruiting
MitoQ is commercially available as a dietary supplement and it has been tested as a potential drug in other diseases, but it has never been tested in patients with sickle cell disease. The goal of this research is to study if MitoQ, a molecule that works as an antioxidant by removing potentially damaging agents in a living organism, improves platelet function in patients with sickle cell disease (SCD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Magee Women's Hospital, Pittsburgh, Pennsylvania +4 locations
Conditions: Sickle Cell Disease
Register for Updates
Blood Sampling for Research Related to Sickle Cell Disease
NCT00542230
Recruiting
This study will collect representative blood samples from healthy children and adults and from children and adults who have unique red blood cell features that are related to sickle cell disease. Sickle cell disease is a blood disease that limits the ability of red blood cells to carry oxygen throughout the body. The purpose of the study is to collect a variety of blood samples that may then be used to investigate advances and potential new drug treatments for sickle cell disease. Volunteers mu... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/13/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Sickle Cell Trait, Sickle Cell Disease, Sickle Cell Anemia
Register for Updates
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
NCT04819841
Recruiting
This study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary objective is to evaluate safety of the treatment in this patient population, as well as preliminary efficacy and pharmacodynamic data.
Gender:
ALL
Ages:
Between 12 years and 40 years
Trial Updated:
06/12/2025
Locations: Lucile Packard Children's Hospital, Palo Alto, California +2 locations
Conditions: Sickle Cell Disease
Register for Updates
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
NCT04657822
Recruiting
This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator.
Gender:
ALL
Ages:
Between 6 months and 100 years
Trial Updated:
06/11/2025
Locations: University Of Alabama, Birmingham, Alabama +28 locations
Conditions: Sickle Cell Disease
Register for Updates
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir
NCT05169580
Recruiting
This is a study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Pociredir in participants with sickle cell disease.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/05/2025
Locations: University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas +22 locations
Conditions: Sickle Cell Disease, Sickle Cell Anemia
Register for Updates
The Efficacy and Safety of Rilzabrutinib in Patients Aged 10 to 65 Years With Sickle-cell Disease
NCT06975865
Recruiting
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential study (Part A), followed by an open-label LTE period (Part B) to investigate the efficacy, and safety of rilzabrutinib in participants with sickle-cell disease (SCD). Study details include: * Study duration: a 52-week double-blind period (Part A), followed by an open-label LTE period (Part B). Double-blind period has two parts, 50% (adult only) until the interim analysis, and 50% (adu... Read More
Gender:
ALL
Ages:
Between 10 years and 65 years
Trial Updated:
05/26/2025
Locations: Bioresearch Partners- Site Number : 8400005, Hialeah, Florida +1 locations
Conditions: Sickle Cell Disease
Register for Updates
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
NCT03937817
Recruiting
Background: Blood disorders like sickle cell disease and malaria affect many people around the world. Researchers want to learn more about blood disorders. To do this, they need to collect biological samples from people with blood disorders. They also need to collect samples from healthy people. Objective: To collect samples to use for research on blood disorders. Eligibility: People ages 18-70 who have blood disorders. Healthy volunteers without blood disorders are also needed. Design: P... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/24/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Sickle Cell Disease, Malaria, Human Physiology, Alpha and Beta Thalassemia
Register for Updates
Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease
NCT06944067
Recruiting
The purpose of this research study is to look at genes and determine how they interact with each other to find changes that could explain why some people's immune systems may respond to blood transfusions. This response is called an alloimmune response. We strongly believe that when someone has an alloimmune response, it is caused by changes in their genes. We plan to compare changes in the genes of individuals that develop red blood cell alloimmunization after blood transfusions with those that... Read More
Gender:
ALL
Ages:
Between 2 years and 99 years
Trial Updated:
05/21/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Sickle Cell Disease
Register for Updates